Search results
Results from the Go Local Guru Content Network
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health ...
Bausch Health Companies' stock was also up today by 10.7% at the same time, so it seems the market believes B+L would get a good premium to where shares traded yesterday in a sale. That would ...
On Thursday, Bausch Health Companies (NYSE:BHC) reported a second-quarter 2024 GAAP EPS of $0.03 compared to the consensus of $0.28. The company reported revenues of $2.403 billion, up 11% year ...
Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would spin off the eye-care company. The ...
Title. Chairman and CEO, Emergent BioSolutions. Term. Feb 2024-. Board member of. Emergent BioSolutions. Children. 3. Joseph C. Papa (born October 1, 1955) is an American businessman and the chairman and chief executive officer (CEO) of Bausch & Lomb, a company formed from the initial public offering (IPO) of the eye health business of Bausch ...
Bausch & Lomb (since 2010 stylized as Bausch + Lomb[2]) is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, [3] lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. [4][5] The company was founded in Rochester, New ...
ROCHESTER, NY — Governor Andrew M. Cuomo announced Tuesday that Bausch + Lomb, a global eye health company and a wholly owned subsidiary of Bausch Health Companies Inc., will grow its contact ...
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.